000131608 001__ 131608
000131608 005__ 20240228145609.0
000131608 0247_ $$2doi$$a10.1093/neuonc/nox093
000131608 0247_ $$2pmid$$apmid:28482026
000131608 0247_ $$2pmc$$apmc:PMC5716199
000131608 0247_ $$2ISSN$$a1522-8517
000131608 0247_ $$2ISSN$$a1523-5866
000131608 0247_ $$2altmetric$$aaltmetric:19998298
000131608 037__ $$aDKFZ-2017-06240
000131608 041__ $$aeng
000131608 082__ $$a610
000131608 1001_ $$0P:(DE-He78)fe53b38061056c5d390f37ce8d63f505$$aSchmidt, Christin$$b0$$eFirst author$$udkfz
000131608 245__ $$aPreclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients.
000131608 260__ $$aOxford$$bOxford Univ. Press$$c2017
000131608 3367_ $$2DRIVER$$aarticle
000131608 3367_ $$2DataCite$$aOutput Types/Journal article
000131608 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521464886_14509
000131608 3367_ $$2BibTeX$$aARTICLE
000131608 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000131608 3367_ $$00$$2EndNote$$aJournal Article
000131608 520__ $$aEmbryonal tumor with multilayered rosettes (ETMR) is a rare and aggressive embryonal brain tumor that solely occurs in infants and young children and has only recently been recognized as a separate brain tumor entity in the World Health Organization classification for CNS tumors. Patients have a very dismal prognosis with a median survival of 12 months upon diagnosis despite aggressive treatment. The aim of this study was to develop novel treatment regimens in a preclinical drug screen in order to inform potentially more active clinical trial protocols.We have carried out an in vitro and in vivo drug screen using the ETMR cell line BT183 and its xenograft model. Furthermore, we have generated the first patient-derived xenograft (PDX) model for ETMR and evaluated our top drug candidates in an in vitro drug screen using this model.BT183 cells are very sensitive to the topoisomerase inhibitors topotecan and doxorubicin, to the epigenetic agents decitabine and panobinostat, to actinomycin D, and to targeted drugs such as the polo-like kinase 1 (PLK1) inhibitor volasertib, the aurora kinase A inhibitor alisertib, and the mammalian target of rapamycin (mTOR) inhibitor MLN0128. In xenograft mice, monotherapy with topotecan, volasertib, and actinomycin D led to a temporary response in tumor growth and a significant increase in survival. Finally, using multi-agent treatment regimens of topotecan or doxorubicin combined with methotrexate and vincristine, the response in tumor growth and survival was further increased compared with mice receiving single treatments.We have identified several promising candidates for combination therapies in future clinical trials for ETMR patients.
000131608 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000131608 588__ $$aDataset connected to CrossRef, PubMed,
000131608 7001_ $$aSchubert, Nil A$$b1
000131608 7001_ $$0P:(DE-He78)b0b3740107f746e09dc23fdf25eb0629$$aBrabetz, Sebastian$$b2
000131608 7001_ $$0P:(DE-He78)e73a0a4fab40344d89d693cbe1df3109$$aMack, Norman$$b3
000131608 7001_ $$0P:(DE-He78)9ce969bf1ac7913b3f2b1cf4dd7f823e$$aSchwalm, Benjamin$$b4$$udkfz
000131608 7001_ $$aChan, Jennifer A$$b5
000131608 7001_ $$0P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e$$aSelt, Florian$$b6
000131608 7001_ $$aHerold-Mende, Christel$$b7
000131608 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b8
000131608 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b9
000131608 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b10
000131608 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b11
000131608 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b12$$eLast author
000131608 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/nox093$$gVol. 19, no. 12, p. 1607 - 1617$$n12$$p1607 - 1617$$tNeuro-Oncology$$v19$$x1523-5866$$y2017
000131608 909CO $$ooai:inrepo02.dkfz.de:131608$$pVDB
000131608 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fe53b38061056c5d390f37ce8d63f505$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000131608 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b0b3740107f746e09dc23fdf25eb0629$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000131608 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e73a0a4fab40344d89d693cbe1df3109$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000131608 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9ce969bf1ac7913b3f2b1cf4dd7f823e$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000131608 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000131608 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000131608 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000131608 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000131608 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000131608 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000131608 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000131608 9141_ $$y2017
000131608 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000131608 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000131608 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2015
000131608 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000131608 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000131608 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000131608 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000131608 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000131608 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000131608 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000131608 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2015
000131608 9201_ $$0I:(DE-He78)G340-20160331$$kG340$$lKKE Pädiatrische Onkologie$$x0
000131608 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x1
000131608 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x2
000131608 980__ $$ajournal
000131608 980__ $$aVDB
000131608 980__ $$aI:(DE-He78)G340-20160331
000131608 980__ $$aI:(DE-He78)B062-20160331
000131608 980__ $$aI:(DE-He78)G380-20160331
000131608 980__ $$aUNRESTRICTED